The SNPs that actually affect how you process nutrients

A consumer DNA report will happily list you several hundred SNPs. Most of them don’t matter. A smaller set produces measurable shifts in blood biomarkers. A smaller set still produces shifts large enough — and consistent enough — to change what belongs in your supplement stack.

This article is a filtered list. The SNPs with enough replicated evidence that a clinician might actually change a protocol over them, organized by which nutrient they affect.

What counts as “evidence enough to act”

Before the list, the bar. For a SNP to earn a place in a practitioner protocol, three things usually need to be true:

1. The enzyme has a known, specific job. Folate activation. Caffeine clearance. Iron loading. Vitamin D receptor signaling.
2. The variant produces a measurable change in a blood biomarker. Homocysteine. 25-hydroxy-vitamin D. Ferritin. Not just a statistical association with a disease decades later.
3. It replicates across populations. One study in one cohort is a hypothesis. Ten studies across three continents is a finding.

SNPs that fail any of those tests still show up on consumer reports. They don’t belong in a protocol.

Folate and methylation: MTHFR C677T and A1298C

The most-studied pair in nutrigenomics, and for good reason.

MTHFR C677T (rs1801133) reduces enzyme activity roughly 30% in heterozygotes and 60–70% in homozygotes [1][2]. Carriers show higher plasma homocysteine on average and reduced capacity to activate folic acid into usable 5-methyltetrahydrofolate. Prevalence varies by population but averages 30–40% globally [3].

MTHFR A1298C (rs1801131) has a smaller solo effect but becomes clinically relevant in compound heterozygotes (one copy of each variant), first described in the late 1990s [4].

What to do: retest homocysteine, supply bioactive folate directly. Methyl Folate Plus™ delivers L-5-MTHF plus folinic acid — the two forms that bypass the MTHFR step entirely. For the broader methylation cycle, see our what is MTHFR primer.

B12 handling: TCN2, FUT2, MTRR

Folate doesn’t work without B12. Several variants affect how efficiently B12 gets from your gut into your cells.

TCN2 c.776C>G (rs1801198) changes transcobalamin II — the protein that carries B12 into cells. The clinical literature on holotranscobalamin (active B12) levels in carriers is mixed; some studies associate the variant with altered holoTC or cardiovascular outcomes and others do not [5]. The practical implication for a practitioner is the same: if B12 symptoms persist despite a normal serum B12, checking holoTC or methylmalonic acid (MMA) can surface a functional deficit.

MTRR A66G (rs1801394) sits in methionine synthase reductase, the enzyme that reactivates B12 inside the methylation cycle. Works most visibly in combination with MTHFR variants.

FUT2 variants affect gut absorption of B12 and are loosely associated with serum B12 levels.

What to do: if methylation-cycle variants are known, monitor homocysteine and methylmalonic acid (MMA) — MMA rises first in functional B12 shortfall. Supplement with methylcobalamin or hydroxocobalamin rather than cyanocobalamin when you want to avoid an extra conversion step. Our B12 forms compared walks through the three options.

Vitamin D: VDR and GC

VDR polymorphisms (FokI, BsmI, TaqI) change the shape of the vitamin D receptor. Effect sizes are smaller than MTHFR but consistent across studies of bone health, immune response, and vitamin D status.

GC (group-specific component) variants change vitamin D binding protein levels, which affects how much 25-OH-D actually reaches tissue.

What to do: test serum 25-hydroxy-vitamin D, aim for 40–60 ng/mL under practitioner guidance, pair D3 with K2 and magnesium (the cofactors D depends on). See our vitamin D cofactors article for the stack.

Q&A: If I don’t have any of these variants, does nutrigenomics matter for me?

Q: My genetic report came back “all normal” on the methylation and folate genes. Does that mean I can skip bioactive vitamins?

A: Probably. A person with no significant variants in the folate, B12, and methylation pathways, who eats a diet with adequate leafy greens and B12 sources (or supplements a basic multi), is unlikely to gain much from aggressive methyl-donor loading. Where nutrigenomics changes the calculus is for the 30–40% of people with MTHFR variants, the smaller fraction with compound B12-handling issues, and anyone whose homocysteine runs above 9 µmol/L despite a reasonable diet. The honest answer: without variants or elevated biomarkers, a basic bioactive B-complex is fine insurance, not a requirement. If variants are present, something like Methylation Complete™ is the daily support protocol most practitioners reach for — and our beyond MTHFR testing article covers the other methylation-cycle genes worth checking.

Caffeine: CYP1A2 rs762551

CYP1A2 rs762551 sorts people into fast (AA) and slow (AC/CC) metabolizers of caffeine. A 2016 genome-wide study of caffeine metabolites confirmed CYP1A2 as the dominant genetic driver of caffeine clearance and habitual coffee-drinking behavior [6].

What to do: slow metabolizers tend to feel caffeine for 8–10 hours versus 3–5 in fast metabolizers — so a 2pm coffee becomes a 10pm sleep disruptor. There’s also observational evidence that slow metabolizers show higher cardiovascular risk at high daily doses. If you’re a slow metabolizer, the practical advice is: one cup in the morning, nothing after noon.

Iron: HFE C282Y and H63D

HFE C282Y (rs1800562) and H63D (rs1799945) are the classic hereditary hemochromatosis variants. Homozygotes for C282Y, and compound heterozygotes (C282Y/H63D), can load iron slowly over decades.

What to do: if you carry these variants, do not take iron supplements or high-iron multivitamins without practitioner guidance and annual ferritin + transferrin saturation monitoring. Men are at higher risk than menstruating women.

Fat handling: APOE ε4

APOE ε4 is the most-studied cardiovascular and neurodegenerative-risk allele. Carriers show a larger LDL response to dietary saturated fat and may benefit more from a Mediterranean-style pattern [7]. In the precision-nutrition Alzheimer’s literature, ε4 carriers are now treated as a distinct nutritional subpopulation [8].

What to do: if you’re an ε4 carrier, the clinical pattern is: keep saturated fat moderate, emphasize monounsaturates (olive oil, nuts), ensure omega-3 intake, watch LDL particle number more than LDL-C alone.

Antioxidant defense: GSTM1, GSTT1, GSTP1

Glutathione S-transferase gene deletions (GSTM1-null, GSTT1-null) reduce phase II detoxification capacity. The effect size is smaller than the methylation variants but relevant in combination — especially for patients with high environmental exposure or already-stressed glutathione status.

What to do: support glutathione precursors (NAC, glycine, cysteine-rich protein) and the cofactors for its recycling (selenium, riboflavin). Our glutathione master antioxidant article covers the full picture.

FTO and MC4R: the “obesity” variants

FTO rs9939609 and MC4R rs17782313 are the two most-replicated genetic contributors to BMI — but the effect per copy is small (1–3 lb across a population). They’re worth knowing because the response to low-calorie diets appears genotype-dependent, not because any single variant dooms or frees you.

What to do: don’t over-interpret. These variants mean satiety biology may be running against you; they don’t change the arithmetic of energy balance.

What to do with this list

Four operating principles, built from nutrigenomics reviews and clinical experience:

1. Know your biomarker before you act. Variant plus normal biomarker rarely needs intervention. Variant plus abnormal biomarker is the case for acting.
2. Supply the bypass in its active form. Slow folate enzyme → 5-MTHF. Reduced B12 transport → methylcobalamin or hydroxocobalamin. Reduced glutathione recycling → NAC plus cofactors.
3. Retest in 8–12 weeks. Homocysteine, ferritin, 25-OH-D, MMA — these are the scoreboard.
4. Treat the person, not the SNP. Two people with identical genotypes can need opposite interventions depending on diet, lifestyle, and other labs.

For a comprehensive panel that covers most of the SNPs above, GenePro+ is the buccal-swab test built for practitioner protocols. For the methylation and B-vitamin side specifically, Methylation Complete™ is the daily stack most carriers start with.

---

This article is educational and does not constitute medical advice. Genetic-variant interpretation and supplementation protocols should be individualized with a qualified practitioner.

References

1. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995. PMID: 7647779
2. Liew SC, Gupta ED. MTHFR C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015. PMID: 25449138
3. Yafasova A, et al. Is the prevalence of MTHFR C677T polymorphism associated with ultraviolet radiation in Eurasia? J Hum Genet. 2012. PMID: 22992775
4. van der Put NM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene. Am J Hum Genet. 1998. PMID: 9545395
5. Bosco P, et al. Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease. J Thromb Haemost. 2006. PMID: 16894458
6. Cornelis MC, et al. Genome-wide association study of caffeine metabolites. Hum Mol Genet. 2016. PMID: 27702941
7. Minihane AM, et al. ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc Nutr Soc. 2007. PMID: 17466101
8. Norwitz NG, et al. Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers. Nutrients. 2021. PMID: 33921683